Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of citations and Altmetric scores (Errington et al., 2014) . This Registered Report describes the proposed replication plan of key experiments from "Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous 'mRNAs' by Tay and colleagues, published in Cell in 2011 . The experiments to be replicated are those reported in Figures 3C, 3D , 3G, 3H, 5A and 5B, and in Supplemental Figures 3A and B . Tay and colleagues proposed a new regulatory mechanism based on competing endogenous RNAs (ceRNAs), which regulate target genes by competitive binding of shared microRNAs. They test their model by identifying and confirming ceRNAs that target PTEN. In Figure 3A and B, they report that perturbing expression of putative PTEN ceRNAs affects expression of PTEN. This effect is dependent on functional microRNA machinery ( Figure 3G and H) , and affects the pathway downstream of PTEN itself ( Figures 5A and B) .
Introduction microRNAs are one of the first identified classes of non-coding RNAs that can modulate the expression of mRNA-coding transcripts by binding to complementary regions in a target gene's sequence and repressing its expression. Thus, expression levels and availability of these microRNAs can influence gene expression, and there is growing evidence that misregulation of microRNAs is correlated with some forms of cancer (Sen et al., 2014) . Naturally occurring microRNA 'sponges' have been shown to be effective in regulating gene expression by altering the levels of their cognate microRNAs (Choi et al., 2007; Karreth and Pandolfi 2013) . Poliseno and colleagues proposed that pseudogenes, long non-coding RNAs with strong homology to coding sequences, could act as the modulators of gene expression as microRNA sponges (Poliseno et al., 2010) . They demonstrated that the pseudogene PTENP1 could regulate the expression levels of PTEN via their cognate microRNAs miR-19b and miR-20a (Poliseno et al., 2010) .
In this study, Tay and colleagues expanded upon the previous work to propose a unifying hypothesis of regulatory networks composed of competing endogenous RNAs (ceRNAs) Sen et al., 2014; Kartha and Subramanian, 2014) . They suggest that protein-coding RNAs, not just non-coding RNAs, can cross-regulate each other based on competition for shared microRNA regulators; ceRNAs can titrate microRNAs from their target genes .
Continuing their focus on the regulation of PTEN, one of the most frequently mutated genes in cancer (Song et al., 2012) , Tay and colleagues propose a computational model to identify ceRNAs de novo, termed MuTaME. Using MuTaME, they identified potential ceRNA regulators of PTEN, and validated if these candidate ceRNAs could modulate PTEN expression in a microRNA-dependent manner .
In Figure 3C , Tay and colleagues examine if silencing ceRNAs targeting PTEN would affect the expression levels of a luciferase construct carrying the 3'UTR of PTEN. They co-transfected DU145 cells with siRNAs against the candidate PTEN ceRNAs along with a luciferase-PTEN 3'UTR construct and measured luciferase activity. After confirming knockdown of each target ceRNA (Supplemental Figure 3A ), they reported that the loss of three of their candidate ceRNAs -SERINC1, VAPA and CNOT6L, but not ZNF460 -reduced the luciferase activity of the PTEN 3'UTR construct. This experiment will be replicated in Protocol 1.
In Figure 3D , they demonstrated that only the 3'UTRs of the candidate ceRNAs were required to affect changes in the luciferase activity of the PTEN 3'UTR construct. Ectopic overexpression of the 3'UTRs of the three candidate ceRNAs relieved inhibition of the PTEN 3'UTR, as evidenced by increased luciferase activity as compared to controls. This experiment will be replicated in Protocol 2.
To test if this effect was dependent on microRNAs, Tay and colleagues repeated these experiments in DICER1 mutant HCT116 cells, in which the machinery required for microRNA function is abrogated. Transfection of wild type HCT116 cells with siRNAs targeting the candidate ceRNAs showed a marked reduction in PTEN protein levels, an effect that was not seen in the DICER1 mutant HCT116 cells (Figures 3G and H) . Knockdown of the candidate ceRNAs was confirmed by RT-PCR (Supplemental Figure 3B ). This experiment will be replicated in Protocol 3.
PTEN negatively regulates the PI3K/AKT pathway (Stambolic et al., 1998) , so Tay and colleagues examined if ceRNA modulation affected the phosphorylation of AKT. Loss of CNOT6L and VAPA in DU145 cells elevated pAKT levels after serum stimulation, an effect that was also observed in wild-type HCT116 cells ( Figure 5A ). However, this effect was abrogated in DICER1 mutant HCT116 cells ( Figure  5A ). They also examined the effect of ceRNAs on the tumorigenic properties conferred by loss of PTEN. Silencing of the ceRNAs CNOT6L and VAPA increased cell proliferation of DU145 cells and wildtype HCT116 cells, similar to silencing of PTEN directly ( Figure 5B ). This effect was less pronounced in DICER1 mutant HCT116 cells ( Figure 5B ). These experiments will be replicated in Protocol 4 and 5.
Two papers published simultaneously provide support for the actions of ceRNA regulatory networks. Karreth and colleagues, from the same lab as Tay and colleagues, demonstrated in vivo evidence for the actions of ceRNA regulation using the sleeping beauty transposase system in a mouse model of melanoma to identify and confirm putative PTEN ceRNAs . Karreth and colleagues identified CNOT6L as a putative PTEN ceRNA through the sleeping beauty transposase system, providing further evidence that CNOT6L is indeed involved in PTEN regulation. Karreth and colleagues focused on ZEB2; using siRNA silencing, they reported that the loss of ZEB2 reduced PTEN protein levels, and affected downstream phosphorylation of AKT . As seen in Tay and colleagues, these effects were dependent on functional microRNA processing; ZEB2 depletion did not affect PTEN levels in DICER1 mutant HCT116 cells . Sumazin and colleagues used a bioinformatics approach to identify post-translational regulation and elucidated over 7,000 genes they proposed acted as miRNA sponges. By comparing the miRNA programs of genes, they could identify genes with common miR programs, indicating the potential for miRNA-mediated crosstalk between those two genes (Sumazin et al., 2011) . They tested their findings by exploring the regulation of PTEN, demonstrating that silencing of putative miRNA program-mediated regulators (mPRs) of PTEN decreased PTEN expression, and, conversely, that the perturbation of PTEN levels could inversely affect the expression of its mPRs. These manipulations also affected tumor cell growth rates, indicating potential in vivo effects of changes to mPR regulatory networks (Sumazin et al., 2011) . Since the publication of these three papers, numerous other examples of ceRNA regulation have been reported in muscle differentiation (Cesana et al., 2011) , human embryonic stem cell renewal (Wang et al., 2013) , regulation of sex determination by SRY (Granados-Riveron and Aquino-Jarquin 2014), breast cancer (Yang et al., 2014; Zheng et al., 2015a; 2015b) , lymphoma (Karreth et al., 2015) and the regulation of the tumor-related HMGA1 (Esposito et al., 2014 ).
The Pandolfi group followed up on their 2011 paper by generating a mathematical model to predict optimal conditions for ceRNA activity, based on a molecular titration mechanism whose effects were correlated to the relative levels of the ceRNA and its target (Ala et al., 2013) . They then tested their in silico predictions by experimentally exploring the effect of VAPA on PTEN expression. While silencing of VAPA did decrease PTEN expression in all five cell lines tested, they noted that the amount of silencing was correlated with the initial VAPA:PTEN expression ratio (Ala et al., 2013) . However, Denzler and colleagues challenge the notion that perturbations in ceRNA expression levels could affect target genes at all (Denzler et al., 2014) . Denzler and colleagues and Ala and colleagues both state that ceRNA effects are dependent on the kinetics of binding, which in turn relies upon the ratio of microRNAs to target sites; increasing the number of target sites through expression of ceRNAs is postulated to affect target gene repression. By quantifying the absolute copy number of the well-studied highly abundant miR-122 and its target sites, Denzler and colleagues showed that large, physiologically unlikely changes in ceRNA expression levels would be required to alter the microRNA: target site ratio enough to perturb target gene expression, casting doubt on the ability of these putative ceRNAs to affect changes in target gene expression levels (Broderick and Zamore 2014; Denzler et al., 2014) . This view was contradicted by Bosson and colleagues, who identified over 3,000 high affinity target sites they claimed could be affected by ceRNAs due to low endogenous microRNA: target site ratios (Bosson et al., 2014) . The activity and impact of potential ceRNA networks is an area of active interest (for review, see de Giorgio et al., 2013) .
Materials and methods
Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab.
Protocol 1: Knock-down of ceRNA network genes results in decreased PTEN-3'UTR luciferase expression This protocol describes how to silence expression of ceRNA network genes and measure effects on PTEN expression by measuring PTEN 3'UTR luciferase activity, as seen in Figures 3C . All cells will be sent for mycoplasma testing and STR profiling.
. DU145 cells are maintained in DMEM supplemented with 10% FBS, # 100 U/ml penicillin/100 mg/ml streptomycin, and # 2 mM glutamine at 37˚C in 5% CO 2 in a humidified atmosphere. This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper, and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Known differences from the original study All known differences are listed in the materials and reagents section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Extracted RNA integrity will be reported with A 260/280 and A 260/230 absorbance ratios, and transfection efficiency will be checked using the siGLO control. qRT-PCR will be performed to confirm the silencing of ceRNA expression. The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded, and the procedure will be maintained for the remaining replicates. All data obtained from the experiment -raw data, data analysis, control data and quality control datawill be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/oblj1/). 
Sampling
. This experiment will include six biological replicates for a minimum power of 88%.
&
See Power calculations for details.
. Each experiment consists of DU145 cells co-transfected with a luciferase-PTEN 3'UTR reporter construct and: . All cells will be sent for mycoplasma testing and STR profiling.
. DU145 cells are maintained in DMEM supplemented with 10% FBS, # 100 U/ml penicillin/100 g/ml streptomycin, and # 2 mM glutamine at 37˚C in 5% CO 2 in a humidified atmosphere.
1. Transfect DU145 cells with PTEN 3'UTR and ceRNA 3'UTRs: a. Separate DU145 cells into 6 different cultures. i. These will be biological replicates. b. Seed cells at 1.2 x 10 5 cells per well in 12 well dishes and incubate for 24 hr. i. Seed 1 well per biological replicate: 7 transfections x 6 replicates.
1. 42 wells total seeded. c. Prepare the transfection mix by adding 100 ng of psiCHECK-2+PTEN3'UTR and 1 mg of 3'UTR plasmid to 100 ml of Opti-MEM. i. Transfect one well per replicate with each of the following:
. empty vector control d. In a separate tube, mix 2 ml of Lipofectamine 2000 with 100 ml of Opti-MEM.
i. Scale the volume of reagents accordingly.
ii. Incubate for 10 min. 
Confirmatory analysis plan
. Statistical Analysis of the Replication Data:
Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non-parametric Wilcoxon-Mann-Whitney test.
&
One-way ANOVA of luciferase activity in DU145 cells expressing 3'UTRs SER, VAPA 3'U1, VAPA 3'U2, CNO 3'U1, CNO 3'U2, PTEN, or empty vector control with the following Bonferroni-corrected planned comparisons:
. Luciferase activity in each 3'UTR transfection vs. the empty vector control (6 comparisons total).
.
Meta-analysis of original and replication attempt effect sizes:
& This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Provisions for quality control
The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. All data obtained from the experiment -raw data, data analysis, control data and quality control data -will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/oblj1/). 
Sampling
. The experiment will be repeated four times (Western blot) and three times (qRT-PCR) for a minimum power of 80%. 
Materials and reagents

Confirmatory analysis plan
Note: At the time of analysis, we will test for normality and homoscedasticity of the data. If the data appears skewed, we will perform the appropriate transformation to proceed with the proposed statistical analysis. If this is not possible, we will perform the equivalent non- . Meta-analysis of original and replication attempt effect sizes: & This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Provisions for quality control
Extracted RNA integrity will be reported with A 260/280 and A 260/230 absorbance ratios, and transfection efficiency will be checked using the siGLO control. The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. If the efficiency does not reach >90%, then any modifications to the transfection protocol will be recorded. qRT-PCR will be performed to confirm silencing of mRNA expression. Images of Ponceau staining to confirm protein transfer. All data obtained from the experiment -raw data, data analysis, control data, and quality control data -will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/oblj1/).
Protocol 4: Effect of knock-down of ceRNA network genes on cell proliferation
This experiment tests the effects of siRNA-mediated depletion of PTEN, CNOT6L, and VAPA expression on cell proliferation in DU145, HCT116 WT, and HCT116 DICER Ex5 cells. It replicates Figure 5B .
Sampling
. This experiment will be repeated five (DU145 cells) times and four (HCT116 cells) times for a minimum power of 80%. . HCT116 cells (wild-type and mutant) are maintained in DMEM with 10% FBS, # 100 U/ml penicillin/100 mg/ml streptomycin, and # 2 mM glutamine at 37˚C/5% CO 2 in a humidified atmosphere.
. DU145 cells are maintained in DMEM supplemented with 10% FBS, # 100 U/ml penicillin/100 mg/ml streptomycin, and # 2 mM glutamine at 37˚C in 5% CO 2 in a humidified atmosphere.
. All cells will be sent for mycoplasma testing and STR profiling. . siNC vs. each siRNA, for each cell line (6 comparisons total). . Meta-analysis of original and replication attempt effect sizes: & This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot. . Non-coding siRNA vs. each of the ceRNA transfected cells (3 comparisons total).
Known differences from the original study
All known differences are listed in the materials and reagents section above, with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Extracted RNA integrity will be reported with A 260/280 and A 260/230 absorbance ratios, and transfection efficiency will be checked using the siGLO control. Cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded and the procedure will be maintained for the remaining replicates. All data obtained from the experiment -raw data, data analysis, control data and quality control data -will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/oblj1/).
Protocol 5: Knock-down of ceRNA network genes results in AKT activation
This experiment tests the effects of siRNA-mediated depletion of PTEN, CNOT6L, and VAPA expression on AKT activation in DU145, HCT116 WT, and HCT116 Dicer Ex5 cells. It replicates Figure 5A .
Sampling
. This experiment will be repeated at least 7 times for a minimum power of 80%. The original Western blot data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined. . HCT116 cells (wild-type and mutant) are maintained in DMEM with 10% FBS, # 100 U/ml penicillin/100 mg/ml streptomycin, and # 2 mM glutamine at 37˚C/5% CO 2 in a humidified atmosphere.
Materials and reagents
. All cells will be sent for mycoplasma testing and STR profiling. 
Confirmatory analysis plan
& Two-way ANOVA of normalized pAKT levels of DU145 cells transfected with siRNA for VAPA, CNOT6L, PTEN, or siNC measured at 0 min, 5 min, and 15 min followed by Bonferroni-corrected planned contrasts:
. siNC vs each siRNA, collapsed across all times (3 contrasts total).
Three-way ANOVA (3x4x2) of normalized pAKT levels of HCT116 WT or HCT116 DICER Ex5 cells transfected with siRNA for VAPA, CNOT6L, PTEN, or siNC measured at 0 min, 5 min, and 15 min:
. HCT116 WT cells with the following Bonferroni-corrected planned contrasts:
. siNC vs. each siRNA, collapsed across all times (3 contrasts total). . HCT116 DICER Ex5 cells with the following Bonferroni-corrected planned contrasts:
. siNC vs. each siRNA, collapsed across all times (3 contrasts total). . Meta-analysis of original and replication attempt effect sizes: & The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.
Known differences from the original study All known differences are listed in the materials and reagents section above, with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The cells will be sent for mycoplasma testing confirming lack of contamination and STR profiling confirming cell line authenticity. Transfection efficiency will be recorded for each replicate and any transfection that does not contain >90% efficiency will be excluded and not continue through the rest of the procedure. Any modifications to the transfection protocol will be recorded, and the procedure will be maintained for the remaining replicates. Images of Ponceau staining to confirm protein transfer. All data obtained from the experiment -raw data, data analysis, control data, and quality control data -will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (https://osf.io/oblj1/).
Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:
https://osf.io/c8hb5
Protocol 1
Summary of original luciferase activity data:
. Note: data provided by original authors for Figure 3C siRNA Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007) . 2 A sensitivity calculation was performed since the original data showed a non-significant effect. The effect size that can be detected with 80% power and a sample size n=4 per group is 3.5378.
Test family
. Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.
. ANOVA: Fixed effects, omnibus, one-way: alpha error = 0.05
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007 
Test family
. Two-tailed t test, difference between two independent means, Bonferroni correction: alpha error = 0.01
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) . 1 4 samples per group will be used making the power >99.9%. 2 A sensitivity calculation was performed since the original data showed a non-significant effect. The effect size that can be detected with 80% power and a sample size n=4 per group is 3.3711.
Summary of original qPCR gene expression data:
. Note: data provided by original authors for Figure S3A . We estimated SD to be 0.001, when it was reported as zero. . Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.
. Two-tailed t test, difference from a constant, Bonferroni correction: alpha error = 0.01
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) . Protocol 2 Summary of original Luciferase data:
. Note: data provided by original authors for Figure 3D . Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007) . 
Test family
Power calculations
Test family
. Two-tailed t test, difference between two independent means, Bonferroni correction: alpha error = 0.00833
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) . 1 6 samples per group will be used making the power 96.2%.
2 6 samples per group will be used making the power 99.9%.
Protocol 3
Summary of original Western blot data:
. Note: data provided by original authors for Figure 3H . Power Calculations performed with G*Power software, version 3.1.7 (Faul et al., 2007) . Summary of original mRNA expression data:
. Note: data provided by original authors for Figure S3B . . Due to the large variance, the following parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests listed above.
. Two-tailed t test, difference from a constant (mu=1), Bonferroni correction: alpha error = 0.00625
Power calculations
Test family
. Two-tailed t test, difference between two independent means, Bonferroni correction: alpha error = 0.0167
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) . 
Test family
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) . Protocol 5
Summary of original AKT Activation data
. Note: data provided by original authors for Figure 5A .
&
We used the average band intensity for siNC since they were measured twice. 
Power calculations
. Performed with G*Power software, version 3.1.7 (Faul et al., 2007) .
In order to produce quantitative replication data, we will run the experiment seven times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.
